Sequentially, the consolidated web revenue fell by 1.29 per cent from Rs 125.16 crore, whereas income fell by 1.34 per cent from Rs 843.93 crore in Q2 FY24.
Its earnings earlier than curiosity, taxes, depreciation, and amortisation (Ebitda) was at Rs 212 crore in opposition to Rs 160 crore in the identical quarter of the earlier monetary yr. The Ebitda margin for the December quarter was reported at 25.5 per cent as in opposition to 23 per cent for a similar interval a yr in the past.
The corporate reported a 4 per cent Y-o-Y enhance within the common income per occupied mattress (ARPOB) in Q3 FY24. The rise in income was attributed to a rise in realisation on the hospital’s Gurugram unit. The hospital’s common mattress occupancy grew by 8.7 per cent, at 64.2 per cent.
Worldwide Affected person revenues grew by 6 per cent Y-o-Y to Rs 473 crore within the December quarter, contributing 6 per cent to total hospital enterprise revenues as in opposition to 7 per cent in the identical quarter final fiscal.
Specialties similar to Cardiology (22.2 per cent), Oncology (12.3 per cent), and Neurology (11.4 per cent) have been the best-performing specialties for the hospital in Q3 FY24.
The corporate introduced outcomes post-market hours. International Well being Restricted inventory was up by 1.97 per cent on the NSE to Rs 1,260 apiece.
Commenting on the outcomes for the quarter, Pankaj Sahni, group chief government officer and director, International Well being Restricted stated that each matured and developed models delivered a strong income development of 17 per cent and 33 per cent Y-o-Y respectively. “This development has primarily been pushed by elevated in-patient quantity and improved realisation,” he added.
First Printed: Feb 08 2024 | 10:53 PM IST